公开(公告)号：US12162853B2

公开(公告)日：2024-12-10

申请号：US18100330

申请日：2023-01-23

Applicant: United Therapeutics Corporation

Inventor： Hitesh Batra ,  Liang Guo

IPC: C07D307/93

Abstract: Provided are novel prodrugs of esuberaprost and pharmaceutical compositions thereof, as well as methods of making and methods of using these prodrugs.

公开(公告)号：US12150377B2

公开(公告)日：2024-11-19

申请号：US18222851

申请日：2023-07-17

Applicant: Crius Technology Group, Inc.

Inventor： Phillip Bogdanovich

IPC: H04B1/38 ,  C07C209/60 ,  C07C211/61 ,  C07C217/80 ,  C07D209/86 ,  C07D209/94 ,  C07D213/06 ,  C07D213/16 ,  C07D219/02 ,  C07D221/08 ,  C07D223/26 ,  C07D265/38 ,  C07D279/22 ,  C07D307/91 ,  C07D307/93 ,  C07D311/80 ,  C07D333/76 ,  C07D405/04 ,  C07D405/12 ,  C07D407/12 ,  C07D471/06 ,  C07D487/04 ,  C09B19/00 ,  C09B21/00 ,  C09B57/00 ,  C09B69/00 ,  C09K11/06 ,  H04B3/54 ,  H04B3/56 ,  H04L5/16 ,  H04L12/28 ,  H04L12/40 ,  H04L41/0833 ,  H04L43/00 ,  H04W4/80 ,  H05B47/105 ,  H05B47/115 ,  H05B47/18 ,  H05B47/185 ,  H05B47/19 ,  H10K85/60 ,  H04L43/08 ,  H05B47/175 ,  H10K50/11 ,  H10K50/15 ,  H10K50/17 ,  H10K50/18

Abstract: Methods, systems, and apparatus for monitoring and controlling electronic devices using wired and wireless protocols are disclosed. The systems and apparatus may monitor their environment for signals from electronic devices. The systems and apparatus may take and disambiguate the signals that are received from the devices in their environment to identify the devices and associate control signals with the devices. The systems and apparatus may use communication means to send control signals to the identified electronic devices. Multiple apparatuses or systems may be connected together into networks, including mesh networks, to make for a more robust architecture.

公开(公告)号：US12065420B2

公开(公告)日：2024-08-20

申请号：US17270767

申请日：2019-08-28

Applicant: HARDIE HEALTH LIMITED

Inventor： Peter Thomas Northcote ,  Ameet Jonathan Singh

IPC: A61K36/25 ,  A61P31/04 ,  C07D307/93 ,  C07D307/935

CPC classification number: C07D307/935 ,  A61K36/25 ,  C07D307/93 ,  A61K2236/333 ,  A61K2236/39 ,  A61P31/04

Abstract: Disclosed herein are compositions containing an isolated bioactive compound of Formula (X):




including less than about 2 wt % of halifordin. Also disclosed are methods for obtaining and using compositions containing the isolated bioactive compound.

公开(公告)号：US20240124409A1

公开(公告)日：2024-04-18

申请号：US18519062

申请日：2023-11-26

Applicant: NANJING UNIVERSITY OF CHINESE MEDICINE

Inventor： Lihong HU ,  Jian LIU ,  Qi LV ,  Yang HU ,  Dong DONG ,  Ping WANG ,  Meng YANG

IPC: C07D307/93 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  A61P19/02 ,  A61P19/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00

CPC classification number: C07D307/93 ,  A61P1/16 ,  A61P11/00 ,  A61P13/12 ,  A61P19/02 ,  A61P19/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00

Abstract: The present application discloses a class of guaianolide sesquiterpene lactone derivatives and pharmaceutical use thereof. The guaianolide sesquiterpene lactone derivative or a pharmaceutically acceptable salt thereof is shown as general formula I. In the present application, a class of novel guaianolide sesquiterpene lactone derivatives are found by structural optimization with abundant natural ingredients such as parthenolide and dehydrocostus lactone as raw materials, which derivatives have good inhibitory activity on the activation of the NLRP3 inflammasome, and the chemical stability, water solubility and oral bioavailability of which are significantly improved, and it is verified by experiments that the derivatives have inhibitory effects on the activity of the NLRP3 inflammasome and have potential pharmaceutical applications.

公开(公告)号：US20230399297A1

公开(公告)日：2023-12-14

申请号：US18031893

申请日：2021-10-14

Applicant: Jacobio Pharmaceuticals Co., Ltd.

Inventor： Runze LI ,  Cunbo MA ,  Zhenchang LIAN ,  Jing XIONG ,  Yanping WANG ,  Wei LONG

IPC: C07D209/20 ,  C07C245/18 ,  C07D305/08 ,  C07D307/16 ,  C07D211/66 ,  C07D309/06 ,  C07D307/93 ,  C07D309/08 ,  C07D207/09 ,  C07D493/04 ,  C07D277/30 ,  C07D207/337 ,  C07D263/32 ,  C07D233/64 ,  C07D333/24 ,  C07D213/74 ,  C07D239/20 ,  C07D213/30 ,  C07D313/04 ,  C07D265/30 ,  C07D331/04 ,  A61P35/00

CPC classification number: C07D209/20 ,  C07C245/18 ,  C07D305/08 ,  C07D307/16 ,  C07D211/66 ,  C07D309/06 ,  C07D307/93 ,  C07D309/08 ,  C07D207/09 ,  C07D493/04 ,  C07D277/30 ,  C07D207/337 ,  C07D263/32 ,  C07D233/64 ,  C07D333/24 ,  C07D213/74 ,  C07D239/20 ,  C07D213/30 ,  C07D313/04 ,  C07D265/30 ,  C07D331/04 ,  A61P35/00 ,  C07C2601/18 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/04 ,  C07C2601/02 ,  C07C2601/08

Abstract: The invention relates to novel glutamine analogs, a composition containing the glutamine analogs and the use thereof.

公开(公告)号：US20230280651A1

公开(公告)日：2023-09-07

申请号：US18197244

申请日：2023-05-15

Applicant: SHIN-ETSU CHEMICAL CO., LTD.

Inventor： Teppei ADACHI ,  Shinya YAMASHITA ,  Masaki OHASHI ,  Tomohiro KOBAYASHI ,  Kenichi OIKAWA ,  Takayuki FUJIWARA

IPC: G03F7/004 ,  G03F7/038 ,  G03F7/039 ,  G03F7/11 ,  C07D307/93 ,  C07D493/18 ,  C07D327/04 ,  C08F220/18 ,  C07C381/12

CPC classification number: G03F7/0045 ,  G03F7/0382 ,  G03F7/0397 ,  G03F7/11 ,  C07D307/93 ,  C07D493/18 ,  C07D327/04 ,  C08F220/1807 ,  C08F220/1808 ,  C07C381/12 ,  G03F7/2006

Abstract: A resist composition containing: (A) a resin containing a repeating unit having an acid-labile group; (B) a photo-acid generator shown by a general formula (B-1); and (C) a solvent, where W1 represents a cyclic divalent hydrocarbon group having 4 to 12 carbon atoms and containing a heteroatom; W2 represents a cyclic monovalent hydrocarbon group having 4 to 14 carbon atoms and not containing a heteroatom; Rf represents a divalent organic group shown by the following general formula; and M+ represents an onium cation. This provides a resist composition and a patterning process that uses the resist composition that show a particularly favorable mask dimension dependency (mask error factor: MEF), LWR, and critical dimension uniformity (CDU) particularly in photolithography where a high-energy beam such as an ArF excimer laser beam is used as a light source.

公开(公告)号：US11667618B2

公开(公告)日：2023-06-06

申请号：US16875606

申请日：2020-05-15

Applicant: WUHAN TIANMA MICROELECTRONICS CO., LTD. ,  WUHAN TIANMA MICROELECTRONICS CO., LTD. SHANGHAI BRANCH

Inventor： Tiezhen Gao ,  Wei Gao ,  Jinghua Niu

IPC: C07D307/93 ,  H01L51/00 ,  C07D333/78 ,  C07D221/18 ,  C07D471/04 ,  C07D487/04 ,  C07D209/82 ,  C07D491/048 ,  C07D495/04 ,  C07D403/14 ,  C07D265/38 ,  C07D409/04 ,  C07D279/18 ,  C07D221/06 ,  C07C211/19

CPC classification number: C07D307/93 ,  C07C211/19 ,  C07D209/82 ,  C07D221/06 ,  C07D221/18 ,  C07D265/38 ,  C07D279/18 ,  C07D333/78 ,  C07D403/14 ,  C07D409/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/048 ,  C07D495/04 ,  H10K85/40 ,  H10K85/622 ,  H10K85/633 ,  H10K85/636 ,  H10K85/6572 ,  H10K85/6574 ,  H10K85/6576 ,  C07C2603/40 ,  H10K50/11

Abstract: The present disclosure provides an azulene ring-containing compound, its use, and an organic photoelectric device including the same. The azulene ring-containing compound is a compound comprising a structure of Formula I. The organic photoelectric device includes an anode, a cathode, and one or more organic thin film layers located between the anode and the cathode; and at least one of the organic thin film layers contains the above-mentioned azulene ring-containing compound comprising the structure of Formula I. The azulene ring-containing compound provided by the present disclosure has an energy level difference ΔEst≤0.3 eV between the lowest singlet state S1 and the lowest triplet state T1, and has a light-emitting mechanism of a thermally activated delayed fluorescent material, and can be used as a thermally activated delayed fluorescent material for organic photoelectric device, so that the light-emitting efficiency of the device is improved.

公开(公告)号：US11634400B2

公开(公告)日：2023-04-25

申请号：US16640138

申请日：2018-08-17

Applicant: University of Rochester

Inventor： Rudi Fasan ,  Simone Giovani ,  Hanan Alwaseem

IPC: C07D307/93 ,  A61P35/02 ,  A61P35/00 ,  C12N9/02

Abstract: The present invention relates to derivatives of the sesquiterpene lactone micheliolide, methods and compositions for their preparation, and methods for using the micheliolide derivatives in pharmaceutical compositions as anticancer and anti-inflammatory agents. The invention also relates to methods for producing micheliolide derivatives modified at positions C2 and C14. The invention also relates to methods for producing parthenolide derivatives modified at positions C2 and C14 in conjunction with modifications at position C13, via chemoenzymatic methods. The invention further relates to methods for using parthenolide derivatives for treating cancer and inflammatory diseases.

公开(公告)号：US11628146B2

公开(公告)日：2023-04-18

申请号：US16938577

申请日：2020-07-24

Applicant: The Regents of the University of California

Inventor： Rhonda R. Voskuhl

IPC: A61K31/05 ,  C07D307/93 ,  C07D487/04 ,  C07D307/82 ,  A61K31/137 ,  A61K31/225 ,  A61K38/21 ,  A61K45/06 ,  A61K38/13 ,  C07C39/42

Abstract: The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand.

公开(公告)号：US11560363B2

公开(公告)日：2023-01-24

申请号：US17287320

申请日：2019-10-17

Applicant: United Therapeutics Corporation

Inventor： Hitesh Batra ,  Liang Guo

IPC: C07D307/93

Abstract: Provided are novel prodrugs of esuberaprost and pharmaceutical compositions thereof, as well as methods of making and methods of using these prodrugs.